Marie Bosslett, Assistant Editor

In case you missed it, this week we had news about the approval of cemiplimab as adjuvant immunotherapy for high-risk CSCC, FDA safety communication on RF microneedling, dermatologists' role in breast cancer awareness, and more.

This review of the latest dermatologic studies highlights new research on hidradenitis suppurativa, including associated pediatric comorbidities, CO2 laser treatment, impact on sexual health, and more.

Vishal A. Patel, MD, discusses cemiplimab's FDA approval as a groundbreaking adjuvant therapy for high-risk cutaneous squamous cell carcinoma patients.

FDA warns of serious risks associated with RF microneedling, urging patient education and careful provider training to ensure safety in aesthetic dermatology.

Mobile app SkinTracker enhances atopic dermatitis care through remote assessments, proving effective and convenient for patients while saving costs.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of October.

Kachiu Lee, MD, MPH, FAAD, shares insights on aesthetic dermatology at the 2025 PDPA Keystone, emphasizing trust and communication over technology for optimal results.

A novel 4% glycyrrhetinic acid scalp gel shows rapid relief for mild to moderate seborrheic dermatitis, enhancing treatment options with herbal ingredients.

Topical dapsone shows promise in treating various mucocutaneous diseases, including rosacea and neutrophilic dermatoses, with a favorable safety profile.

Regeneron's cemiplimab-rwlc gains FDA approval as the first immunotherapy for high-risk cutaneous squamous cell carcinoma, significantly improving disease-free survival.

Explore the latest advancements in retinoid technology with AlphaRet, enhancing skin tolerability and efficacy for diverse patient needs.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

In case you missed it, this week we had news about roflumilast's expanded access for children as young as 2, LP-10 for oral lichen planus, SYX-5219's IND clearance, and more.

Amy Lewis, MD, integrates Glo2Facial into her practice to enhance patient relationships and promote early skin health through innovative aesthetic treatments.

A study reveals ixekizumab's effectiveness in treating mild to moderate plaque psoriasis, showing superior PASI responses and improved long-term outcomes.

Discover how the Glo2Facial revolutionizes aesthetic dermatology with innovative skin oxygenation and customizable treatments for radiant, youthful skin.

New research highlights the psychosocial impact of rosacea on Chinese patients, linking lifestyle factors and comorbidities to quality of life.

Explore real-world psoriasis management insights from Anthony Nuara, MD, PhD, focusing on patient-centered approaches and innovative treatments like tildrakizumab.

A new trial reveals that combining Excimer laser with JAK inhibitors significantly enhances vitiligo treatment outcomes, ensuring safety and durability.

This review of the latest dermatologic studies highlights new research on mitigating irritation from 0.1% retinol, OTC therapies for alopecia, the perception of skin lesions by HCPs in the delivery room, and more.

New research highlights the link between isotretinoin dosage and increased chronic hand eczema, emphasizing the need for careful monitoring during acne treatment.

Lipella Pharmaceuticals' LP-10 shows promise as a targeted treatment for OLP, offering safety and efficacy in recent trials, according to Michael Chancellor, MD.

Sitryx Therapeutics advances SYX-5219 for moderate to severe AD, aiming for a first-in-class oral treatment with potential for lasting disease remission.

Brian Kim, MD, FAAD, explores the transformative role of neuroimmunology in dermatology, urging a shift towards systems-level therapeutic strategies.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

In case you missed it, this week we had news about the FDA approvals of guselkumab for pediatric plaque psoriasis and PsA, along with remibrutinib for CSU, LEO Pharma's acquisition of spesolimab for GPP, and more.

Brian Kim, MD, FAAD, explores the Cell Symposia: Neuro-immune Axis, highlighting neuroimmunology's impact on dermatology and systemic medicine.

WHO includes adalimumab and ustekinumab for psoriasis, plus sunscreen for albinism, enhancing global skin health and access to essential treatments.

Lisa Espinoza, MD, highlights the importance of patient education and tailored HA filler treatments for achieving natural cosmetic results.

Heather Gates, PA-C, brings her dermatology expertise into a conference management business to enhance education for professionals of all levels.